Blanton Jesse D, Meadows Anastasia, Murphy Staci M, Manangan Jamie, Hanlon Cathleen A, Faber Marie-Luise, Dietzschold Bernhard, Rupprecht Charles E
Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia, 30333, USA.
J Wildl Dis. 2006 Jul;42(3):663-6. doi: 10.7589/0090-3558-42.3.663.
Oral vaccination of free-ranging wildlife is a promising technique in rabies control. The small Asian mongoose (Herpestes javanicus) is an important reservoir of rabies on several Caribbean islands, but no vaccines have been evaluated for this species. Captive mongooses were used to test the safety and efficacy of the commercially licensed vaccinia-rabies glycoprotein (V-RG) recombinant vaccine and a newly developed genetically engineered oral rabies virus vaccine (SPBNGA-S). In one study using V-RG, no vaccinated animals developed detectable rabies virus-neutralizing antibodies, and all but one died after experimental challenge with rabies virus. In contrast, all animals given SPBNGA-S demonstrated seroconversion within 7 to 14 days after vaccination and survived rabies virus challenge. On the basis of these preliminary results indicating the greater efficacy of SPBNGA-S vs. V-RG vaccine, additional investigations will be necessary to determine the optimal dose and duration of vaccination, as well as incorporation of the SPBNGA-S vaccine into edible bait.
对自由放养的野生动物进行口服疫苗接种是狂犬病防控中一项很有前景的技术。亚洲小爪水獭(爪哇獴)是加勒比地区几个岛屿上狂犬病的重要宿主,但尚未对该物种的疫苗进行评估。圈养水獭被用于测试商业许可的痘苗病毒-狂犬病糖蛋白(V-RG)重组疫苗和新开发的基因工程口服狂犬病病毒疫苗(SPBNGA-S)的安全性和有效性。在一项使用V-RG的研究中,没有接种疫苗的动物产生可检测到的狂犬病病毒中和抗体,并且在狂犬病病毒实验性攻击后,除一只外全部死亡。相比之下,所有接种SPBNGA-S的动物在接种后7至14天内出现血清转化,并在狂犬病病毒攻击中存活下来。基于这些初步结果表明SPBNGA-S疫苗比V-RG疫苗更有效,有必要进行进一步调查以确定最佳接种剂量和持续时间,以及将SPBNGA-S疫苗纳入可食用诱饵中。